Cancer Cells Restrict Necessary Cell Division
Targeted therapeutics is a type of cancer treatment that uses drugs to precisely 'target' cancer cells without affecting normal cells. Although targeted therapy is an effective treatment, many individuals prefer to use it in combination with other therapies such as traditional or standard chemotherapy, surgery, or radiation therapy. Developments in research for DNA changes and proteins that drive cancer are proving effective to design promising treatments that target such proteins. For different types of cancers come different types of drugs that individually target distinct cancer. However, tumors are tested to check the target, and provide therapy if the drugs are available. As traditional chemotherapy can damage normal cells while killing cancer cells, the targeted therapeutics market is expected to witness growth during the forecast period.
Targeted therapy varies in types with the primary objective to help treat cancer by intervening with particular proteins that help tumors develop and circulate throughout the body. The human body functions with the immune system constantly working to find the problems and fight. However, cancer cells can hide from the immune system making it difficult to kill. Specific targeted therapy can mark the cancer cells to make it easier for the immune system to target and destroy them. Some targeted therapies can help in boosting the immune system so it works efficiently against cancer. Furthermore, human body cells divide themselves when needed. Cells receive signals that attach to proteins on the cell surface, indicating cells to divide. Thus, a body recreates the cells continuously depending on the body requirements. However, cancer cells can make changes in proteins, which can restrict cell division, affecting the body. Types of targeted therapy interfere with the proteins that prevent the cell division process. This process helps to slow down the cancer growth in the body. With an increasing number of cancer patients across the world, the global targeted therapeutics market is likely to grow during the forecast period.
To know the scope of our report Get a Sample on Targeted Therapeutics Market
Lack of Availability of Resources, Patient Care During COVID-19 Pandemic Affecting Cancer Treatment
The COVID-19 pandemic has hit healthcare services in multiple dimensions. The healthcare industry is witnessing several obstacles varying from suspending the routine patient flow to healthcare equipment. Moreover, overwhelming healthcare supplies, implementation of extra emergency measures, and social distancing with expanded utilization of tele-health and virtual medicine are some of the common situations across most healthcare facilities. As a prudent approach, oncology applications implemented explicit measures such as decreasing the number of patients in outpatient dispensaries, reducing redundant or elective procedures, and discharging patients from inpatient services. All the factors are contributing to the slowdown of the healthcare industry and hindering the expansion of the targeted therapeutics market to a certain extent.
The COVID-19 pandemic has detrimentally impacted cancer care across the world. Patients with cancer are defenseless people predisposed to many harms during crisis and virus pandemics, including susceptivity to life-threatening viruses and suspension of their cancer or usual medical care. Oncologists across the globe are facing major challenges to provide high-quality constant unfragmented cancer treatment while reducing a patient's risk to exposure during care. The pandemic is likely to affect more in nations with low or developing economy resulting in inadequate resources, sparse infrastructure, deficiency of healthcare providers and coordinated care teams, deficiency of medical equipment and personal protective equipment (PPE), and poor access to technology. Thus, the COVID-19 is likely to leave a mark on the global targeted therapeutics market post-pandemic.
Get a glimpse of the in-depth analysis through our Report Brochure
Growing Number of Cancer Patients Requires Advanced Treatment Therapies
The International Agency for Research on Cancer (IARC) has estimated more than 19 million cancer patients in 2020. Nearly 10 million of those patients have died from cancer-related conditions. The number of cancer patients is expected to tremendously increase, reaching more than 27 million new cancer cases by 2040. Healthcare industry and governing organizations are constantly taking measures and investing more in cancer treatment and drugs to avoid such casualties. Targeted therapy is proving to be an efficient potential treatment with promising therapeutic outcomes across a broad range of cancers. High pervasiveness and growing number of cancer patients across the world are predicted to advance the growth of the global targeted therapeutics market during the forecast period. Thus, the global targeted therapeutics market is anticipated to expand at a CAGR of ~2% from 2021 to 2031.
Variety of Techniques to Treat Cancer Relieves Stress of Recovering Patients
The progress in biotechnology allowed the synthesis of certain biological molecules in microorganisms and other existing cells utilizing the recombinant DNA technology. The world of biologics has grown to encompass a broad range of products. The increase in investment and continues innovative approaches for cancer treatments have led to the rise of biologics in recent years. In addition, some of the targeted therapeutics monoclonal antibodies come in the world's best-selling drugs. On the other hand, small molecule drugs that can enter cells readily due to their low molecular weight are proving efficient to affect other molecules, such as proteins and may cause cancer cells to die. The small-molecule drugs and therapeutic proteins vary considerably in many of their class properties. However, different physicochemical properties not only affect the pharmacological aspects, but also the reliability, efficiency, and manufacturing quality of the drugs.
Compared to monoclonal antibodies, small molecule drugs are relatively uncomplicated synthetic compounds and can be produced by chemical synthesis. The pharmacological exercise, balance, and permeability of small molecules mainly depend on chemistry as opposed to fundamental synergies. Due to their attributes, small-molecule drugs can be determined in a variety of ways, including orally. Their oral bioavailability is certainly a distinct advantage over biologics in drug reinforcement. The growing popularity of various techniques in the targeted therapeutics market is influencing healthcare administrations and patients toward it, and is expected to increase in demand during the forecast period.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Targeted therapy comprises drugs that obstruct increase and proliferation of cancer by interfering with particular molecules that are involved in the expansion of carcinogenic cells. The world is expected to witness increasing incidences of cancers such as breast cancer, lung cancer, colorectal cancer, and gastrointestinal cancer, among others, thus boosting the global targeted therapeutics market. However high expenses of these drugs, along with increased cost of molecular diagnostic tests to detect cancer are anticipated to hamper the growth of the targeted therapeutics market. Nevertheless, increasing investments in cancer research, improving insurance coverage, and rising number of new targeted anti cancer drugs are projected to overcome all the restraints of the targeted therapeutics market during the forecast period.
Targeted Therapeutics Market: Overview
- According to Transparency Market Research’s latest report on the global targeted therapeutics market for the historical period of 2017–2019 and forecast period of 2021–2031, increase in incidence of cancer across the globe, surge in global geriatric population, and rise in product approvals are projected to drive the global targeted therapeutics market during the forecast period
- According to the report, the global targeted therapeutics market was valued over US$ 67.8 Bn in 2020 and is anticipated to expand at a CAGR of ~2% from 2021 to 2031
Increase in Product Approvals Globally: Key Drivers
- Increase in the number of product approvals for the treatment of different types of cancer, along with robust pipeline products in early and late phases of clinical trials is expected to augment the global targeted therapeutics market during the forecast period
- For instance, in March 2020, Sanofi’s Sarclisa was approved in combination with pomalidomide and dexamethasone in the U.S. for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and by the European Commission in June 2020. Sarclisa has presently been launched in the U.S., Austria, Japan, Switzerland, Canada, and the U.K.
- Novartis’s Kisqali (ribociclib) data demonstrates consistent efficacy benefit with Kisqali plus endocrine therapy across the primary intrinsic subtypes of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer
- Rise in demand for the treatment leads to expansion of product pipeline and increase in product approvals, which in turn drives the global targeted therapeutics market
Promising Pipeline of Anticancer Drugs to Boost Market
- Robust R&D studies are underway for the development of new drugs and therapies for cancer. Several products of different companies are in different phases of clinical trials and will be available in the market during the forecast period.
- According to the Pharmaceutical Research and Manufacturers of America (PhRMA), around 836 drugs and vaccines were in different clinical stages for cancer in 2016
- For instance, Pfizer’s Crizotinib, an oral inhibitor of the ALK gene that is mutated in about 5% of patients with NSCLC, produced unprecedented response rates in a phase 2 study
- Other market players have developed target therapies for cancer that are in different clinical phases. These developments are likely to propel the global targeted therapeutics market during the forecast period.
High Cost of Treatment to Hamper Global Market
- Targeted therapies that aim at specific genetic biomarkers have been widely adopted in the treatment of several cancer types
- Tyrosine kinase inhibitors have become standard first-line therapy for patients with advanced NSCLC harboring EGFR mutations or ALK-gene rearrangements; however, these are expensive medications, costing thousands of dollars per month
- In 2019, J&J mentioned in an article that Janssen’s Balversa (erdafitinib) was the first FGFR inhibitor approved by the FDA. This drug costs around US$ 10,080 to US$ 22,680 for a 28-day supply.
- Hence, high cost of targeted therapy is likely to hamper the growth of the global targeted therapeutics market during the forecast period
Targeted Therapeutics Market: Competition Landscape
- This report profiles major players in the global targeted therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
- The global targeted therapeutics market is highly consolidated, with small number of players holding majority share
- Leading players operating in the global targeted therapeutics market include
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca
- Bristol-Myers Squibb Company
- Bayer AG, Merck & Co., Inc.
- Novartis AG
- GlaxoSmithKline plc
- Merck KGaA
- Sanofi
- Seagen, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
Targeted Therapeutics Market: Key Developments
- Key players in the global targeted therapeutics market are engaged in new product launches, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the global targeted therapeutics market. A few expansion strategies adopted by players operating in the global targeted therapeutics market include:
- In March 2021, Amgen and Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, announced an agreement under which Amgen will acquire Five Prime Therapeutics for US$ 38.00 per share in cash, representing an equity value of approximately US$ 1.9 Bn. This acquisition adds Five Prime's innovative pipeline to Amgen's leading oncology portfolio.
- In September 2020, Sanofi acquired Principia Biopharma, Inc. for US$ 3.68 Bn (EUR 3.2 Bn). This acquisition will strengthen the core areas of autoimmune and allergic diseases, giving Sanofi full control of tolebrutinib (SAR442168), as well as additional BTK inhibitors to develop further.
- The report on the global targeted therapeutics market discussed individual strategies, followed by company profiles of manufacturers of targeted therapeutics. The competition landscape section has been included in the report to provide readers with a dashboard view of key players operating in the global targeted therapeutics market.
Targeted Therapeutics Market - Segmentation
| Type |
|
| Application |
|
| Distribution Channel |
|
| Region |
|
Frequently Asked Questions
What is the total market worth of targeted therapeutics market?
Targeted therapeutics market was valued over US$ 67.8 Bn in 2020 and to reach valuation of ~US$ 87 bn by 2031
What is the anticipated CAGR of the targeted therapeutics market in the forecast period?
Targeted therapeutics market is anticipated to expand at a CAGR of ~2% from 2021 to 2031
What are the key driving factors for the growth of the targeted therapeutics market?
Targeted therapeutics market is driven by increase in the number of product approvals for the treatment of different types of cancer, along with robust pipeline products in early and late phases of clinical trials
Which region is expected to project the highest market share in the global targeted therapeutics market?
North America dominated the global targeted therapeutics market, followed by Europe, and the trend is anticipated to continue during the forecast period
Who are the key players in the global targeted therapeutics market?
Key players operating in the global targeted therapeutics market include Amgen, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Bayer AG, Merck & Co., Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Targeted Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Targeted Therapeutics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Cancer Prevalence and Incidence Rate by Key Region
5.2. Clinical Trial Pipeline Analysis
5.3. Key Industry Events
5.4. COVID-19 Pandemics Impact on Global Targeted Therapeutics Market
6. Global Targeted Therapeutics Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.1.1. Angiogenesis Inhibitors
6.3.1.2. HER-2 Targeted Agents
6.3.1.3. Anti-CD20 Monoclonal Antibodies
6.3.2. Small Molecule
6.3.2.1. Tyrosine Kinase Inhibitors
6.3.2.2. mTOR Inhibitors
6.3.2.3. PARP Inhibitors
6.4. Global Targeted Therapeutics Market Attractiveness Analysis, by Type
7. Global Targeted Therapeutics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
7.3.1. Breast Cancer
7.3.2. Colorectal Cancer
7.3.3. Leukemia
7.3.4. Lung Cancer
7.3.5. Lymphoma
7.3.6. Multiple Sclerosis
7.3.7. Renal Cancer
7.3.8. Wet Age-related Macular Degeneration
7.3.9. Others
7.4. Global Targeted Therapeutics Market Attractiveness Analysis, by Application
8. Global Targeted Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel
9. Global Targeted Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Targeted Therapeutics Market Attractiveness Analysis, by Region
10. North America Targeted Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.1.1. Angiogenesis Inhibitors
10.2.1.2. HER-2 Targeted Agents
10.2.1.3. Anti-CD20 Monoclonal Antibodies
10.2.2. Small Molecule
10.2.2.1. Tyrosine Kinase Inhibitors
10.2.2.2. mTOR Inhibitors
10.2.2.3. PARP Inhibitors
10.3. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
10.3.1. Breast Cancer
10.3.2. Colorectal Cancer
10.3.3. Leukemia
10.3.4. Lung Cancer
10.3.5. Lymphoma
10.3.6. Multiple Sclerosis
10.3.7. Renal Cancer
10.3.8. Wet Age-related Macular Degeneration
10.3.9. Others
10.4. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. North America Targeted Therapeutics Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Distribution Channel
10.6.3. By Country
11. Europe Targeted Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.1.1. Angiogenesis Inhibitors
11.2.1.2. HER-2 Targeted Agents
11.2.1.3. Anti-CD20 Monoclonal Antibodies
11.2.2. Small Molecule
11.2.2.1. Tyrosine Kinase Inhibitors
11.2.2.2. mTOR Inhibitors
11.2.2.3. PARP Inhibitors
11.3. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
11.3.1. Breast Cancer
11.3.2. Colorectal Cancer
11.3.3. Leukemia
11.3.4. Lung Cancer
11.3.5. Lymphoma
11.3.6. Multiple Sclerosis
11.3.7. Renal Cancer
11.3.8. Wet Age-related Macular Degeneration
11.3.9. Others
11.4. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Targeted Therapeutics Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Distribution Channel
11.6.3. By Country/Sub-region
12. Asia Pacific Targeted Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.1.1. Angiogenesis Inhibitors
12.2.1.2. HER-2 Targeted Agents
12.2.1.3. Anti-CD20 Monoclonal Antibodies
12.2.2. Small Molecule
12.2.2.1. Tyrosine Kinase Inhibitors
12.2.2.2. mTOR Inhibitors
12.2.2.3. PARP Inhibitors
12.3. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
12.3.1. Breast Cancer
12.3.2. Colorectal Cancer
12.3.3. Leukemia
12.3.4. Lung Cancer
12.3.5. Lymphoma
12.3.6. Multiple Sclerosis
12.3.7. Renal Cancer
12.3.8. Wet Age-related Macular Degeneration
12.3.9. Others
12.4. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Targeted Therapeutics Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Distribution Channel
12.6.3. By Country/Sub-region
13. Latin America Targeted Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.1.1. Angiogenesis Inhibitors
13.2.1.2. HER-2 Targeted Agents
13.2.1.3. Anti-CD20 Monoclonal Antibodies
13.2.2. Small Molecule
13.2.2.1. Tyrosine Kinase Inhibitors
13.2.2.2. mTOR Inhibitors
13.2.2.3. PARP Inhibitors
13.3. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
13.3.1. Breast Cancer
13.3.2. Colorectal Cancer
13.3.3. Leukemia
13.3.4. Lung Cancer
13.3.5. Lymphoma
13.3.6. Multiple Sclerosis
13.3.7. Renal Cancer
13.3.8. Wet Age-related Macular Degeneration
13.3.9. Others
13.4. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Targeted Therapeutics Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Distribution Channel
13.6.3. By Country/Sub-region
14. Middle East & Africa Targeted Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.1.1. Angiogenesis Inhibitors
14.2.1.2. HER-2 Targeted Agents
14.2.1.3. Anti-CD20 Monoclonal Antibodies
14.2.2. Small Molecule
14.2.2.1. Tyrosine Kinase Inhibitors
14.2.2.2. mTOR Inhibitors
14.2.2.3. PARP Inhibitors
14.3. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
14.3.1. Breast Cancer
14.3.2. Colorectal Cancer
14.3.3. Leukemia
14.3.4. Lung Cancer
14.3.5. Lymphoma
14.3.6. Multiple Sclerosis
14.3.7. Renal Cancer
14.3.8. Wet Age-related Macular Degeneration
14.3.9. Others
14.4. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Distribution Channel
14.6.3. By Country/Sub-region
15. Competitive Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. Sanofi
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Strategic Overview
15.2.1.5. SWOT Analysis
15.2.2. GlaxoSmithKline plc
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Strategic Overview
15.2.2.5. SWOT Analysis
15.2.3. Takeda Pharmaceutical Company Limited
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Strategic Overview
15.2.3.5. SWOT Analysis
15.2.4. Merck & Co., Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Strategic Overview
15.2.4.5. SWOT Analysis
15.2.5. Novartis AG
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Strategic Overview
15.2.5.5. SWOT Analysis
15.2.6. Merck KGaA
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Strategic Overview
15.2.6.5. SWOT Analysis
15.2.7. Pfizer Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Strategic Overview
15.2.7.5. SWOT Analysis
15.2.8. F. Hoffmann-La Roche Ltd.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Strategic Overview
15.2.8.5. SWOT Analysis
15.2.9. AstraZeneca
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. Strategic Overview
15.2.9.5. SWOT Analysis
15.2.10. Seagen, Inc.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. Strategic Overview
15.2.10.5. SWOT Analysis
15.2.11. Bayer AG
15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.11.2. Financial Overview
15.2.11.3. Product Portfolio
15.2.11.4. Strategic Overview
15.2.11.5. SWOT Analysis
15.2.12. Amgen, Inc.
15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.12.2. Financial Overview
15.2.12.3. Product Portfolio
15.2.12.4. Strategic Overview
15.2.12.5. SWOT Analysis
15.2.13. Bristol-Myers Squibb Company
15.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.13.2. Financial Overview
15.2.13.3. Product Portfolio
15.2.13.4. Strategic Overview
15.2.13.5. SWOT Analysis
List of Tables
Table 01: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 02: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017-2031
Table 03: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017-2031
Table 04: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 05: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 06: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 09: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031
Table 10: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule , 2017–2031
Table 11: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 12: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 16: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 17: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 19: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 21: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031
Table 22: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017–2031
Table 23: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 25: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 27: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031
Table 28: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017–2031
Table 29: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 30: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 31: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 32: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 33: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Monoclonal Antibodies, 2017–2031
Table 34: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Small Molecule, 2017–2031
Table 35: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 36: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Targeted Therapeutics Market Value Share, by Application, 2020
Figure 03: Global Targeted Therapeutics Market Value Share, by Distribution Channel, 2020
Figure 04: Global Targeted Therapeutics Market Value Share, by Type, 2020
Figure 05: Global Targeted Therapeutics Market Value Share, by Region, 2020
Figure 07: Global Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031
Figure 06: Global Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031
Figure 08: Global Targeted Therapeutics Market Value (US$ Mn), by Monoclonal Antibodies, 2017-2031
Figure 09: Global Targeted Therapeutics Market Value (US$ Mn), by Small Molecule, 2017-2031
Figure 10: Global Targeted Therapeutics Market Value (US$ Mn), by Angiogenesis Inhibitors, 2017-2031
Figure 11: Global Targeted Therapeutics Market Value (US$ Mn), by HER-2 Targeted Agents, 2017-2031
Figure 12: Global Targeted Therapeutics Market Value (US$ Mn), by Anti-CD20 Monoclonal Antibodies, 2017-2031
Figure 13: Global Targeted Therapeutics Market Value (US$ Mn), by Angiogenesis Inhibitors, 2017-2031
Figure 14: Global Targeted Therapeutics Market Value (US$ Mn), by mTOR Inhibitors, 2017-2031
Figure 15: Global Targeted Therapeutics Market Value (US$ Mn), by PARP Inhibitors, 2017-2031
Figure 17: Global Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031
Figure 16: Global Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031
Figure 18: Global Targeted Therapeutics Market Value (US$ Mn), by Breast Cancer, 2017-2031
Figure 19: Global Targeted Therapeutics Market Value (US$ Mn), by Colorectal Cancer, 2017-2031
Figure 20: Global Targeted Therapeutics Market Value (US$ Mn), by Leukemia, 2017-2031
Figure 21: Global Targeted Therapeutics Market Value (US$ Mn), by Lung Cancer, 2017-2031
Figure 22: Global Targeted Therapeutics Market Value (US$ Mn), by Lymphoma, 2017-2031
Figure 23: Global Targeted Therapeutics Market Value (US$ Mn), by Multiple Sclerosis, 2017-2031
Figure 24: Global Targeted Therapeutics Market Value (US$ Mn), by Renal Cancer, 2017-2031
Figure 25: Global Targeted Therapeutics Market Value (US$ Mn), by Wet Age-related Macular Degeneration, 2017-2031
Figure 26: Global Targeted Therapeutics Market Value (US$ Mn), by Others, 2017-2031
Figure 28: Global Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 27: Global Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 29: Global Targeted Therapeutics Market Value (US$ Mn), by Hospital Pharmacies, 2017-2031
Figure 30: Global Targeted Therapeutics Market Value (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 31: Global Targeted Therapeutics Market Value (US$ Mn), by Online Pharmacies, 2017-2031
Figure 32: Global Targeted Therapeutics Market Value Share Analysis, by Region, 2020 and 2031
Figure 33: Global Targeted Therapeutics Market Attractiveness Analysis, by Region, 2021–2031
Figure 34: North America Targeted Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 35: North America Targeted Therapeutics Market Value Share Analysis, by Country, 2020 and 2031
Figure 36: North America Targeted Therapeutics Market Attractiveness Analysis, by Country, 2021–2031
Figure 37: North America Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031
Figure 38: North America Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031
Figure 39: North America Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031
Figure 40: North America Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031
Figure 41: North America Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 42: North America Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 43: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 44: Europe Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2030
Figure 45: Europe Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021–2030
Figure 46: Europe Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031
Figure 47: Europe Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031
Figure 48: Europe Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031
Figure 49: Europe Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031
Figure 50: Europe Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 51: Europe Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 52: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 53: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2030
Figure 54: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021–2030
Figure 55: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031
Figure 56: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031
Figure 57: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031
Figure 58: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031
Figure 59: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 60: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 61: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 62: Latin America Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2030
Figure 63: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021–2030
Figure 64: Latin America Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031
Figure 65: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031
Figure 66: Latin America Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031
Figure 67: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031
Figure 68: Latin America Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 69: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 70: Middle East & Africa Targeted Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 71: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2030
Figure 72: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021–2030
Figure 73: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Type, 2020 and 2031
Figure 74: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Type, 2021–2031
Figure 76: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Application, 2020 and 2031
Figure 75: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Application, 2021–2031
Figure 77: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 78: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2021–2031
